[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  BioSpace [@biospace](/creator/twitter/biospace) on x 25.1K followers Created: 2025-06-23 15:29:59 UTC After consistently failing to meet investor expectations, @novonordisk touted a safety profile for CagriSema in line with the GLP1-RA class, while reporting mid-stage data for its GLP1- and amylin-targeting drug amycretin that raised dosing questions. #glp1 #obesity #biospace XXX engagements  **Related Topics** [investment](/topic/investment) [$nvo](/topic/$nvo) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/biospace/status/1937171284774777046)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
BioSpace @biospace on x 25.1K followers
Created: 2025-06-23 15:29:59 UTC
After consistently failing to meet investor expectations, @novonordisk touted a safety profile for CagriSema in line with the GLP1-RA class, while reporting mid-stage data for its GLP1- and amylin-targeting drug amycretin that raised dosing questions.
#glp1 #obesity #biospace
XXX engagements
Related Topics investment $nvo stocks healthcare
/post/tweet::1937171284774777046